Aldoketo reductase (AKR) inhibitors having formulas I-III are used to treat disorders associated with NO/SNO deficiency.

Aldoketo reductase (AKR) inhibitors having formulas I-III are used to treat disorders associated with NO/SNO deficiency.

Aminocyclobutane compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions:

##STR00001##

wherein X, R.sup.1, R.sup.2a, R.sup.2b, R.sup.3 and R.sup.4 are defined herein.

Aminocyclobutane compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions:

##STR00001##

wherein X, R.sup.1, R.sup.2a, R.sup.2b, R.sup.3 and R.sup.4 are defined herein.

Disclosed are compounds of Formula 1, all stereoisomers, N-oxides, and salts thereof,

##STR00001##

wherein G is CONR.sup.5R.sup.6 or selected from

##STR00002## and R.sup.1 through R.sup.18, R.sup.f and G are as defined in the Disclosure.

Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of a compound or a composition of the invention.

Provided in the present invention are a novel tricyclic aromatic heterocyclic compound and a preparation method therefor, a pharmaceutical composition and a use thereof. Specifically, provided in the present invention is a compound as shown in formula I below, or an optical isomer, a hydrate, a solvate thereof, or a pharmaceutically acceptable salt thereof. The definitions of each group are as specified in the description. The compound of formula I can be used for treating diseases related to a PD-1/PD-L1 signaling pathway.

##STR00001##

The present application relates to a compound of Chemical Formula 1 and an organic light emitting device including the same.

The present application relates to a compound of Chemical Formula 1 and an organic light emitting device including the same.

The present disclosure relates to three different types of host materials, and an organic electroluminescent device comprising the same, and it is possible to provide an organic electroluminescent device having higher luminous efficiency and/or improved lifetime properties compared to a conventional organic electroluminescent device.

The present disclosure relates to three different types of host materials, and an organic electroluminescent device comprising the same, and it is possible to provide an organic electroluminescent device having higher luminous efficiency and/or improved lifetime properties compared to a conventional organic electroluminescent device.